◆ TICKERBASEVisão interativa →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Início › Todas as ações › RUBICON · English version

Rubicon Research Limited (RUBICON)

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant.

Números-chave

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados2026-03-312025-03-31
Receita total₹17.3B₹12.7B
Lucro bruto₹11.5B₹8.8B
Resultado Operacional (EBIT)₹3.6B₹2.2B
Resultado líquido₹2.5B—

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de RUBICON. /companies/us/RUBICON

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.